

## UNITED STATES DEPARTMENT OF COMMERCE **Patent and Trademark Office**

DATE MAILED:

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 08/986,545 12/08/97 DULLE HM42/0622 **EXAMINER** VIKKI H AUDIA, PHD KEALING, D PHARMACOPEIA, INC. 101 COLLEGE ROAD **ART UNIT** PAPER NUMBER PRINCETON NJ 08540 1613

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

# Office Action Summary

Application No. 08/986,545

Applicant(s)

Dolle III et al.

Examiner

**Dominic Keating** 

Group Art Unit 1613



□ Bassassina ta communication(s) filed on	
Responsive to communication(s) filed on	· · · · · · · · · · · · · · · · · · ·
☐ This action is <b>FINAL</b> .	
Since this application is in condition for allowance except for in accordance with the practice under Ex parte Quayle, 1939	
A shortened statutory period for response to this action is set to is longer, from the mailing date of this communication. Failure application to become abandoned. (35 U.S.C. § 133). Extension 37 CFR 1.136(a).	to respond within the period for response will cause the
Disposition of Claims	
	is/are pending in the application.
Of the above, claim(s)	is/are withdrawn from consideration.
Claim(s)	
X Claim(s) 1-12	
☐ Claim(s)	
☐ Claims	
	are subject to resultation or discison requirement.
Application Papers	
See the attached Notice of Draftsperson's Patent Drawing	
☐ The drawing(s) filed on is/are object	
The proposed drawing correction, filed on	is _approved _disapproved.
☐ The specification is objected to by the Examiner.	
☐ The oath or declaration is objected to by the Examiner.	
Priority under 35 U.S.C. § 119	
☐ Acknowledgement is made of a claim for foreign priority	
☐ All ☐ Some* ☐ None of the CERTIFIED copies or	f the priority documents have been
received.	
☐ received in Application No. (Series Code/Serial Nur	
received in this national stage application from the	International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:	
☐ Acknowledgement is made of a claim for domestic priorit	.y under 35 0.5.C. § 119(e).
Attachment(s)	
Notice of References Cited, PTO-892	-(-)
	o(s)3
<ul><li>Interview Summary, PTO-413</li><li>Notice of Draftsperson's Patent Drawing Review, PTO-94</li></ul>	18
□ Notice of Informal Patent Application, PTO-152	.•
<u>FF</u>	
SEE OFFICE ACTION ON T	HE FULLOWING PAGES

Serial Number: 08/986,545 Page 2

Art Unit: 1613

#### Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-12 are rejected under the judicially created doctrine of double patenting over claims 1-7 of U. S. Patent No. 5,734,054 since the claims, if allowed, would improperly extend the "right to exclude" already granted in the patent.

Serial Number: 08/986,545 Page 3

Art Unit: 1613

The subject matter claimed in the instant application is fully disclosed in the patent and is covered by the patent since the patent and the application are claiming common subject matter, as follows: hydroxy-amino acid amide compounds.

Furthermore, there is no apparent reason why applicant was prevented from presenting claims corresponding to those of the instant application during prosecution of the application which matured into a patent. See *In re Schneller*, 397 F.2d 350, 158 USPQ 210 (CCPA 1968). See also MPEP § 804.

### Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

Claims 1-12 are rejected under 35 U.S.C. 102(e) as being anticipated by Dolle, III et al. (5,734,054). The applicant claims hydroxy amino acid amides according to claim 1, Formula I. Dolle III discloses the hydroxy amino acid amines claimed by the applicant (see claims 1-7 and cols. 2-4).

Art Unit: 1613

## Telephone Inquiry Contacts

3. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dominic Keating whose telephone number is (703) 308-4548. The examiner can normally be reached on Monday through Friday from 9 a.m. to 5:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter, can be reached on (703) 308-4532. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Johann Richter

Supervisory Primary Examiner

Art Unit 1613

Technology Center 1

DJK

June 17, 1998